This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical (ISRG) Rises 5% Post Earnings: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
The Market's Excessive Recession Fears
by Sheraz Mian
We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile (TMUS) and Marsh & McLennan (MMC) and others.
Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?
by Urmimala Biswas
Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.
Medtronic (MDT) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Medtronic (MDT) closed at $80.32 in the latest trading session, marking a -0.61% move from the prior day.
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $80, signifying a +1.65% move from its prior day's close.
Medtronic (MDT) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medtronic (MDT) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Medtronic (MDT) closed at $79.30 in the latest trading session, marking a -0.23% move from the prior day.
Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $78.10, moving +1.32% from the previous trading session.
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $77.06, representing a +0.23% change from its previous close.
Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).
Medtronic Loses 5% in a Month: What's Next for MDT Investors?
by Urmimala Biswas
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Medtronic (MDT) Shares Positive Data for MiniMed 780G System
by Zacks Equity Research
Medtronic (MDT) presents more compelling data showcasing the benefits of the MiniMed 780G system.
3 Generative AI-Based MedTech Stocks to Keep an Eye On
by Moumi Mondal
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes
by Zacks Equity Research
For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.
Top Stock Reports for NVIDIA, Tesla & Linde
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Tesla, Inc. (TSLA) and Linde plc (LIN), as well as two micro-cap stocks Servotronics, Inc. (SVT) and The Cato Corporation (CATO).
Watch These 5 Stocks That Recently Hiked Dividends
by Santanu Roy
Investors may keep a tab on stocks like HLNE, RL, SPTN, EQH and MDT, which have lately hiked their dividend payments.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
by Zacks Equity Research
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
Compared to Estimates, Medtronic (MDT) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Medtronic (MDT) give a sense of how the business performed in the quarter ended April 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Medtronic (MDT) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 0.69% and 1.80%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Medtronic's (MDT) MiniMed 780G AID System Wins New Accolade
by Zacks Equity Research
Medtronic's (MDT) MiniMed 780G system gets recognized among Fast Company's 2024 World Changing Ideas.
Medtronic (MDT) Reports Favorable SPHERE Per-AF Trial Outcome
by Zacks Equity Research
Medtronic's (MDT) Affera Mapping and Ablation System with Sphere-9 Catheter achieves endpoints for safety and efficacy for the treatment of AFib.
Unlocking Q4 Potential of Medtronic (MDT): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.